The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not sufficient to confer full and enduring beneficial effects. We propose that the subjective effects of psychedelics are necessary for their enduring beneficial effects and that these subjective effects account for the majority of their benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because psychedelics are not only beneficial in populations suffering from psychopathologies, but also for those without, enhancing social and cognitive skills such as empathy and creativity, but also general well-being (18, 112).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These associations could reflect target engagement (ketamine-induced glutamate release), leading to dissociative effects, a subsequent elicitation of synaptogenesis and resultant antidepressant response 28,56,57 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes [42, 43].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Given the dose-response relationship between the glutamate surge, synaptogenesis and antidepressant response following ketamine administration 28,56,57 , it is possible that the relationship between derealization and increased SV2A density observed here is mediated by glutamate release.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Self-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citation
Cited by
Items 301–400 of 541
Meaningful Psychedelic Experiences Predict Increased Moral Expansiveness
Olteanu, W., & Moreton, S. G. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2478095 · Cited by 5
“The correlation between changes in moral expansiveness with mystical experiences and ego dissolution provides empirical support for the notion that the enduring psychological effects of psychedelics are rooted in the profound subjective experience itself (Yaden and Griffiths 2021).”
Pasquini, L., Simon, A. J., Gallen, C. L., Kettner, H., Roseman, L., Gazzaley, A. H., Carhart-Harris, R. L., & Timmermann, C. (2025) · Imaging Neuroscience · doi:10.1162/imag_a_00541 · Cited by 5
“…commonly used in the psychedelic field, often indicated by terms such as “acceptance” , “letting-go” , or “surrender” , which have been shown to be key mediators of improved well-being following assisted psychedelic therapy ( Roseman et al., 2018; Wolff et al., 2020; Yaden & Griffiths, 2021).”
Sawyer, D. W. (2022) · Religions · doi:10.3390/rel13111061 · Cited by 6
Davis, A. K., Timmermann, C., Bernal, A., Lancelotta, R., Nayak, S. M., Sepeda, N., Nikolaidis, A., & Griffiths, R. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2232379 · Cited by 7
“…characterize the phenomenology of psychedelic experiences and also to better determine psychological mechanisms which may underlie the therapeutic efficacy for psychedelics in mood, anxiety and substance use disorders, among others (Davis, Barrett, and Griffiths 2020; Yaden and Griffiths 2021).”
Self-citationExpectancies for Subjective and Antidepressant Effects in Psilocybin Users
Earleywine, M., Mian, M. N., & Leo, J. A. D. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231194798 · Cited by 6
Trajectories of sentiment in 11,816 psychoactive narratives
Friedman, S. F., & Ballentine, G. (2023) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2889 · Cited by 6
“…when considering the therapeutic effect of psychedelic ‐ assisted therapy wherein the observed correlation between mystical experience and clinical efficacy is likely to be conditioned by the precise sequential dynamics and emotional content of the acute experience (Yaden & Griffiths, 2021).”
BackgroundPhotoswitchable TCB-2 for control of the 5-HT 2A receptor and analysis of biased agonism
Esmaeili, A. J., Montazeri, P., Gomez, J. C., Dumervil, D. J., Nezhad, F. S., & Steinhardt, R. C. (2024) · Chemical Communications · doi:10.1039/d4cc03892d · Cited by 5
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders
Valdez, T., Patel, V., Senesombath, N., Hatahet-Donovan, Z., & Hornick, M. G. (2024) · Pharmaceuticals · doi:10.3390/ph17111484 · Cited by 6
“In nearly all cases where it has been recorded, those individuals undergoing psychedelic therapy who have the most intense spiritual or mystical experiences on the drug are the ones who perceive the most benefit [48,99,100].”
Kim, S., Yang, S., Jung, J., Choi, J., Kang, M., & Joo, J. (2025) · Advanced Science · doi:10.1002/advs.202413786 · Cited by 10
The conundrum of therapeutic intoxication
Mathai, D. S., Yaden, D. B., & O’Donnell, K. C. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2022.58 · Cited by 5
Self-citationRennie, J., Sjöstedt-Hughes, P., & Morgan, C. J. A. (2023) · Research Square · doi:10.21203/rs.3.rs-3494308/v1 · Cited by 5
Brouwer, A., Brown, J. K., Erowid, E., Erowid, F., Thyssen, S., Raison, C. L., & Carhart-Harris, R. L. (2024) · Research Square · doi:10.21203/rs.3.rs-3941205/v1 · Cited by 5
Falcon, J. (2025) · Critique of Anthropology · doi:10.1177/0308275x251357813 · Cited by 4
“” This has led to different philosophies in terms of what kind of scienti fi c protocols are appropriate within the clinical setting and which phenomena are regarded as worth investigating in the fi rst place (Johnson, 2021; Jylkk¨a, 2021; Yaden and Grif fi ths, 2021).”
Donegan, C. J., Daldegan‐Bueno, D., Noorani, T. N., Sumner, R. L., Forsyth, A., Evans, W., Smith, T., Hoeh, N. R., Sundram, F., Menkes, D. B., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110670 · Cited by 4
Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model
Kandilakis, C. L., & Papatheodoropoulos, C. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00892 · Cited by 5
Psychedelic therapeutics in psychiatric conditions
Harvey, P. D., & Nemeroff, C. B. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02335-z · Cited by 8
Olash, C., Buchanan, D. M., Brown, R. E., Faerman, A., Cherian, K. N., Lin, G., Spiegel, D., Gross, J. J., & Williams, N. (2026) · npj Mental Health Research · doi:10.1038/s44184-026-00185-7 · Cited by 6
“Contemporary psychedelic research suggests that the quality of the subjective experience often predicts clinical outcome 6 – 8 .”
Zahid, Z., Sultan, Z. W., Krause, B. M., Wenthur, C. J., Pearce, R. A., & Banks, M. I. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0061 · Cited by 4
Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease
Tap, S. C., Bostoen, T., Breeksema, J. J., & Schoevers, R. A. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.001 · Cited by 4
Feasibility of a Hypnosis Intervention for a Mystical Experience
Corlett, C. E., Alldredge, C. T., & Elkins, G. R. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2491352 · Cited by 5
“…treatment outcomes of psychedelic-assisted therapy may be influenced more by the subjective effects associated with a psychedelic experience that accompanies psychedelic drug usage than the physiological or neurological effects of the compounds themselves (Yaden & Griffiths, 2021).”
Bhatt, K. V., Asuncion, J. D., Alam, A., Zisook, S., & Stahl, S. M. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.07.001 · Cited by 8
Psychedelics and mental health: reimagining care through science, insight, and compassion
Mikellides, G., & Kyriazis, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1649929 · Cited by 4
Lawrence, D. W., Battista, A. P. D., & Timmermann, C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2230568 · Cited by 6
“…Sanders and Zijlmans 2021); however, recent arguments caution against this approach and recommend valuing the phenomenological features in order to facilitate and/or potentiate therapeutic effects (Aqil and Roseman 2023; Breeksema and van Elk M 2021; Cherniak et al. 2022; Yaden and Griffiths 2021).”
Barber, M., Gardner, J., Liknaitzky, P., & Carter, A. (2024) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12545 · Cited by 6
Belief change and agnostic frames in psychedelic research and clinical contexts
Yaden, D. B., Nayak, S. M., & Griffiths, R. R. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0008 · Cited by 5
Self-citationBarker, S. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111259 · Cited by 5
Exploring serotonergic psychedelics as a treatment for personality disorders
Carrithers, B. M., Roberts, D. E., Weiss, B., King, J. D., Carhart-Harris, R. L., Gordon, A. R., Pagni, B. A., Moreau, M., Ross, S., & Zeifman, R. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110413 · Cited by 4
Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration
Tal, T. B., Pogodin, I., Botvinnik, A., Lifschytz, T., Heresco‐Levy, U., & Lerer, B. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03428-x · Cited by 4
“Nevertheless, it is presumed that SP ef fi cacy requires psychedelic effects, including alterations in consciousness and sensory perception, although this view is not held by all authors [8, 9].”
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action
Miller, E. A., Capone, C., Eaton, E. M., Swift, R. M., & Haass‐Koffler, C. L. (2025) · CNS Drugs · doi:10.1007/s40263-025-01199-z · Cited by 7
“This variability underscores Grof’s description of LSD as a “nonspecific amplifier of the unconscious” [13], and raises questions about how, exactly, clinical outcomes depend on subjective experience [118].”
Comparing psychedelic and meditation experience reports with natural language processing
Kallio-Mannila, K., Salmela, R., & Jylkkä, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-27724-0 · Cited by 4
Shults, F. L. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2078591 · Cited by 4
“…2021; Yaden et al., 2021; M. W. Johnson et al., 2019; Lebedev et al., 2015) as well as the therapeutic potential of such experiences (Carhart-Harris & Goodwin, 2017; Doblin et al., 2019; Emerson et al., 2014; Johnson, 2018; Lewis-Healey et al., 2021; Wheeler & Dyer, 2020; Yaden & Griffiths, 2020).”
BackgroundLysergic Acid Diethylamide Alters the Effects of Brain Stimulation in Rodents
Dwiel, L. L., Henricks, A. M., Bragg, E. M., Nicol, J., Gui, J., & Doucette, W. T. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0014 · Cited by 5
“3,4 However, it remains unclear whether the mystical experience or other subjective effects are merely a proxy of achieving a therapeutic dose related to another mechanism or whether the experience itself plays a necessary role in therapeutic efficacy.”
A Framework for Assessment of Adverse Events Occurring in Psychedelic Assisted TherapiesPreprint
Palitsky, R., Kaplan, D. M., Perna, J., Bosshardt, Z., Maples‐Keller, J. L., Levin-Aspenson, H. F., Zarrabi, A. J., Peacock, C., Mletzko, T., ROTHBAUM, B. O., et al. (2024) · doi:10.31234/osf.io/h2wfy · Cited by 4
A dual-receptor model of serotonergic psychedelicsPreprint
Juliani, A., Chelu, V., Graesser, L., & Safron, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.12.589282 · Cited by 8
Formoso, K. A. (2023) · Consciousness Spirituality & Transpersonal Psychology · doi:10.53074/cstp.2023.63 · Cited by 3
Psychedelic experiences in psychedelic-assisted therapy for depression
Khan, U. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2378845 · Cited by 3
“Yaden and Griffiths (2020) have argued that the subjective effects of psychedelics are necessary for their therapeutic benefits.”
Adamczyk, S., Paczyńska, M., Ruban, A., Szczypiński, J., Bola, M., & Orlowski, P. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2464797 · Cited by 9
“…intensity and quality of the acute ego dissolution experience to the potential of psychedelics to exert a lasting influence on behavior, beliefs, and psychological functioning (Carhart-Harris and Goodwin 2017; Yaden and Griffiths 2020; Stoliker et al. 2022; for an alternative view see Olson 2020).”
Reckweg, J. T., Mason, N. L., Theunissen, E. L., Svendsen, C. B., Terwey, T. H., & Ramaekers, J. G. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1543640 · Cited by 5
Michael, P., Fritz, P., Gosseries, O., Rousseau, A., Ancion, A., Ghuysen, A., & Martial, C. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1544438 · Cited by 5
Suggestion Effects in Psychedelics: Confounds and Opportunities
Stein, M. V., & Terhune, D. B. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2501964 · Cited by 7
“…of this approach, however, presupposes the hypothesis that the therapeutic benefits of psychedelics are primarily driven by their capacity for inducing anomalous experiences (e.g., ego dissolution) and some evidence supports this (Hack et al., 2023; Lii et al., 2023; Yaden & Griffiths, 2021).”
Koning, E., McMillan, R. M., Keshen, A. R., Hay, P., Fernandez, A. V., Reynolds, J., & Touyz, S. W. (2025) · Journal of Eating Disorders · doi:10.1186/s40337-025-01394-9 · Cited by 4
“The therapeutic importance of the psychedelic experience for EDs is corroborated by the broader PAT literature in which the intensity of the acute experience reliably predicts symptom improvement [5–8].”
Puigseslloses, P., Nadal‐Gratacós, N., Fumàs, B., Modenutti, C. P., Pottie, E., Ortigosa, J., Pablo-Quesada, A., Riera-Colomer, C., Ettcheto, M., Berzosa, X., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03308-2 · Cited by 6
Barker, S. A. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00695 · Cited by 3
Simon, G., Tadmor, N., & Halperin, D. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105074 · Cited by 3
Sanitizing psychedelics: the biopolitics of non-hallucinogenic psychoplastogens
Hartogsohn, I. (2026) · BioSocieties · doi:10.1057/s41292-025-00377-y · Cited by 5
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia‐Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., & Nayak, S. M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117010 · Cited by 4
Self-citationChaplains in Psychedelic Assisted Therapy: Rationale and Competencies
Lewis, S. P., Clark‐Soles, J., Mayorga, O., Sawyer, S. K., Slavet, E., Vidt, B. J., Shanti, S., Wiggins, R., Willis, K., Frey, J., et al. (2026) · Journal of Religion and Health · doi:10.1007/s10943-026-02591-9 · Cited by 4
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5
A critical review of brain entropy as a biomarker of the psychedelic state
Moses, B., Doss, M. K., & Tagliazucchi, E. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106720 · Cited by 5
Bender, D. A., & Siegel, J. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00043-9 · Cited by 4
Integrative Interventions for Improving Outcomes in Depression: A Narrative Review
Halma, M. T. J., Plothe, C., & Marik, P. E. (2024) · Psychology International · doi:10.3390/psycholint6020033 · Cited by 2
General Anesthesia Occludes Ketamine's Antidepressant Response in a Rodent Model of Chronic Stress
Markman, D., Wasilczuk, A. Z., & Cichon, J. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0007 · Cited by 3
Noback, M. N., Kenton, J. A., Klein, A. K., Hughes, Z. A., Kruegel, A. C., Schmid, Y., Halberstadt, A. L., & Young, J. W. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110334 · Cited by 3
David, J., Berkovich‐Ohana, A., & Dor‐Ziderman, Y. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06792-0 · Cited by 6
“These findings align with other studies highlighting the role of acute subjective effects (Yaden and Griffiths 2021), and ego dissolution in particular, as causal in incurring the long-term effects of psychedelics in general (Kałużna et al. 2022), and ayahuasca in particular (Uthaug et al. 2018;…”
Clinical Utility of Mystical Experiences: An Overview and Conceptual Framework
Alldredge, C. T., Vagner, M., Corlett, C. E., & Elkins, G. R. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2526351 · Cited by 4
“Recent psychedelic research has suggested that treatment outcomes may be more dependent on the subjective effects related to an ME than the physiological or neurological effects of the substance itself (Roseman et al., 2017; Rothberg et al., 2021; Yaden & Griffiths, 2021).”
Stanford, S. C. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251360754 · Cited by 3
“It is not known whether either activation of 5-HT2a receptors or a hallucinogenic (mystical) experience, or both, is essential for an antidepressant response to psychedelics (but see: Yaden and Griffiths, 2020).”
Modification of natural tryptamines for the treatment of neuropsychiatric diseases
Palfreyman, M. G., Varty, G. B., Stang, E. M., Boltaev, U., Avery, K., & Nivorozhkin, A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368362 · Cited by 3
“Griffiths and many in the field believed that the therapeutic effects of psychedelics were connected to the subjective effects experienced by the patients during the trip (Yaden and Griffiths, 2021) and were most likely mediated via the 5-HT 2A receptor.”
Yaden, D. B., & Newberg, A. B. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780190665678.003.0012 · Cited by 3
Self-citationA long trip into the universe: Psychedelics and space travel
Lerer, L. B., & Varia, J. C. (2022) · Frontiers in Space Technologies · doi:10.3389/frspt.2022.899159 · Cited by 2
“The profound experience or “trip” associated with psychedelics may improve responses to psychotherapeutic interventions and there is a strong placebo effect (Yaden and Griffiths, 2020).”
Backgroundα-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant
Glennon, R. A., & Dukat, M. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00139 · Cited by 3
da Cruz, L. V. M., Bienemann, B., Palhano-Fontes, F., Tófoli, L. F., de Araújo, D. B., & Mograbi, D. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-44193-5 · Cited by 13
“Trichter et al. 25 explored changes in spirituality in first time ayahuasca users, with their qualitative interviews indicating ten main themes in participants’ reports: presence of light/geometric patterns, sense of honor, respect, gratitude and/or awe, sense of connection, self-reflection and/or…”
Hilal, F. F., Jeanblanc, J., & Naassïla, M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023028 · Cited by 4
Die Rolle der Psychotherapie in klinischen Studien mit Psychedelika
Evens, R., & Wolff, M. (2024) · Die Psychotherapie · doi:10.1007/s00278-024-00715-8 · Cited by 3
Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives
Aday, J. S., Boehnke, K. F., Herberholz, M., & Kruger, D. J. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00354 · Cited by 4
Licit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
“There is mounting evidence that the occurrence and strength of these experiences is correlated with changes in depression scores (61).”
BackgroundPohořalá, V., Kuchař, M., Spanagel, R., & Bernardi, R. E. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.09.006 · Cited by 8
Nigam, K. B., Curseen, K. A., & Beaussant, Y. (2023) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2023.04.004 · Cited by 4
Classic psychedelics: past uses, present trends, future possibilitiesPreprint
Safron, A., & Johnson, M. W. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/eys2j · Cited by 6
Fernández‐Borkel, T., Borkel, L. F., Rojas‐Hernández, J., Hernández‐Álvarez, E., Hernández, D. J. Q., Ponti, L. G., & Henríquez‐Hernández, L. A. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00445 · Cited by 6
“Taken together, these findings support the notion of subjective experience, induced by psychedelics, as a potential requirement to obtain therapeutic benefits, 21 besides the underlying neurobiological mechanisms.”
InfluentialPetrovitch, D., Victor, S. E., Schmidt, A. T., Schmitz, J. M., Meyer, T. D., Stotts, A. L., & Littlefield, A. K. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00371-y · Cited by 3
Pashdag, J. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00385 · Cited by 3
Beesley, V. L., Kennedy, T., Maccallum, F., Ross, M., Harvey, R., Rossell, S. L., Sarris, J. J., Perkins, D., Neale, R. Ε., Bennett–Levy, J., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095992 · Cited by 4
Bhatt, K. V., Compton, J. N., Ellerman-Tayag, E., Mishra, J., Perivoliotis, D., Pittman, J. O. E., Ramanathan, D., & Bismark, A. W. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0040 · Cited by 2
“8,9 10 – 12 The degree to which mystical experiences contribute to the antidepressant effect of psychedelic drugs, however, remains a heavily debated area of research.”
Andión, Ó., Bouso, J. C., Sarris, J. J., Tófoli, L. F., Opaleye, E. S., & Perkins, D. (2025) · PLOS mental health. · doi:10.1371/journal.pmen.0000097 · Cited by 3
“The first has been associated with psychedelic experiences [43,44] and an increased likelihood of experiencing adverse effects [6].”
McMillan, R. M., Fowler, J. A., Erbacher, T., Ireland, R. E. E., Brown, S. J., Brömdal, A., Wang, G., & Mullens, A. B. (2025) · Journal of Homosexuality · doi:10.1080/00918369.2025.2526046 · Cited by 2
Palmisano, V. F., Agnorelli, C., Faraji, S., & Nogueira, J. J. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp01252j · Cited by 2
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Halma, M. T. J., Levy, R., & Varón, J. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100286 · Cited by 2
Meaning and Psychedelics in Palliative Care: A Narrative Review
Alexander, W. B., Hansen, E., Anderson, B. T., Zarrabi, A. J., Rogers, A. H., Loewen, G., Ficcaro, Z. R., Alexander, M. H., Schaefer, D., & Case, A. A. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.10.015 · Cited by 4
Dutton, M., Schwenn, P., Mitchell, J., Hoffmann, P., Bailey, N. W., Fitzgerald, P. B., Lagopoulos, J., & Can, A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251398677 · Cited by 2
“…similar relevance for psilocybin, with individual differences in functional brain connectivity predicting subjective experience – a key determinant of therapeutic outcome Australian & New Zealand Journal of Psychiatry, 60(2) (Goodwin et al., 2025; Siegel et al., 2024; Yaden and Griffiths, 2021).”
Realization experiences: a convergent account of insight and mystical experiences
Kim, J. J., Tulver, K., Aru, J., Kaup, K. K., Pogliani, A., & Laukkonen, R. (2026) · Philosophical Psychology · doi:10.1080/09515089.2026.2613030 · Cited by 4
“For our part, we agree with Yaden and Griffiths (2020) that the lion’s share of evidence and argument suggests that it the experience itself that makes mystical experiences so personally transformative rather than the drug action of psyche-delics, and that those experiences share important…”
Romeo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Mathieu, P., Amirouche, A., Bezo, A., Hacquet, R., Piolino, P., & Benyamina, A. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111621 · Cited by 2
Rowe, T., Hurzeler, T. P., Towers, E., Louie, E., & Morley, K. C. (2026) · Brain and Behavior · doi:10.1002/brb3.71533 · Cited by 4
Kršák, M., Sparrow, D., ROSNER, B. A., DeMolles, D. A., & Shannon, S. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261470523 · Cited by 2
“6,9 Second, this manuscript suggests that expectancy may overlap with the therapeutic mechanism itself rather than function solely as bias.”
InfluentialSkinner, A., & Challis, S. (2023) · Cambridge Archaeological Journal · doi:10.1017/s0959774323000148 · Cited by 2
“In any event, the mechanisms are not as important as the visionary element; it is the subjective experience of ASCs that accounts for their therapeutic potential (Yaden & Grif fi ths 2021).”
BackgroundOn motivating irruptions: the need for a multilevel approach at the interface between life and mind
Cea, I. (2023) · Adaptive Behavior · doi:10.1177/10597123231184651 · Cited by 6
“…a multilevel, pluralistic approach to causation and explanation, such as those being recently discussed in theoretical assessments of psychiatry and psychedelic medicine (Aday et al., 2023; Carhart-Harris, 2018; Gauld et al., 2022; Girn et al., 2023; van Elk & Yaden, 2022; Yaden & Griffiths, 2020).”
BackgroundSchimmelpfennig, J., & Jankowiak-Siuda, K. (2023) · Neuropsychiatria i Neuropsychologia · doi:10.5114/nan.2023.129068 · Cited by 2
Oña, G. (2023) · Quaderns de l'Institut Català d'Antropologia · doi:10.56247/qua.401 · Cited by 4
Aghaei, A. M., Weleff, J., Martins, B. S., Ing, K., Fontenele, R., Barnett, B. S., Anand, A., & Nia, A. B. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00574-y · Cited by 2
“In the context of psychedelic psychotherapy, the central concept revolves around the significance of the “peak experience” [70].”
Chen, Y., Wang, T., Tan, Y., & Li, D. (2024) · Digital Health · doi:10.1177/20552076241249869 · Cited by 3
“” 29 Moreover, a related study by Davis et al. 30 pointed out that the acute psychedelic effect after taking psychedelics, which reduces depression/anxiety, is due to the crucial mediating role of psychological fl exibility.”
BackgroundMaguire, J. (2024) · Studies in Clinical Social Work Transforming Practice Education and Research · doi:10.1080/28376811.2024.2371792 · Cited by 2
Revisiting psychiatry’s relationship with spirituality
DeBonis, K. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1441922 · Cited by 4
Selected Abstracts from the 2024 International Neuroethics Society Annual Meeting
Bissette, H. L., Cecchini, D., Sterner, R., Eskander, E., & Dubljević, V. (2024) · AJOB Neuroscience · doi:10.1080/21507740.2024.2404598 · Cited by 2
Lipson, J., Ford, T., Beattie, M., Garbowit, L., Gordon, H., Kiley, A., Limberis, A., Shnayder, S., & Miller, L. (2024) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2024.2422171 · Cited by 3
“Moreover, in recent years, clinical researchers working with psychedelics have characterized an apparent link between strength of psychedelic-occasioned mystical experience and remission of depression symptoms (Yaden & Griffiths, 2020).”
Synthesizing Attachment Theory with the REBUS Model: An Agenda Proposal for Psychedelic Science
Cherniak, A. D., Carhart-Harris, R. L., Brulin, J. G., Mikulincer, M., Östlind, S., & Granqvist, P. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.17 · Cited by 3
Koning, E., Chaves, C., Kirkpatrick, R. H., & Brietzke, E. M. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01185-8 · Cited by 2
Tsupari, M., Hellman, M., & Tammi, T. (2025) · Contemporary Drug Problems · doi:10.1177/00914509241310766 · Cited by 4
Exploring the Role of Psychedelic Experiences on Wellbeing and Symptoms of Disordered Eating
Loh, N., & Luke, D. P. (2025) · Psychoactives · doi:10.3390/psychoactives4010007 · Cited by 2
“…included a “higher perceived psychedelic experience” (higher intensity of the experience), with “fun” and “self-exploration” as motivations for use (pp. 98–110 More specifically, mystical and insight effects are thought to be a necessary counter-part to positive enduring outcomes [125].”
The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?
Norman, T. R. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.1006105 · Cited by 2
Singh, A. N. A., & de Assis, G. L. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00368-7 · Cited by 3
“These studies should employ both proximal outcomes (integration quality, early behavior change) and distal outcomes (symp - tom maintenance, quality of life, functioning) with extended follow-up periods of at least 12 months [106].”
Kähönen, J. (2025) · Psychoactives · doi:10.3390/psychoactives4040043 · Cited by 2
“…mental health benefits solely to their neurobiological antidepressant effects, Tang overlooks both the controversy surrounding so-called non-hallucinogenic psychedelics and the extensive literature emphasizing the therapeutic importance of the subjective experiences psychedelics induce [4].”
Metadata
- Authors
- Yaden, D. B., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 568-572
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033615
- OpenAlex
- W3113263685
- Cited by
- 541
- References
- 28
- Citations by year
- 2026: 81 · 2025: 125 · 2024: 105 · 2023: 98 · 2022: 92 · 2021: 36 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Steven and Alexandra Cohen Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psychedelics, subjective effects, treatment outcomes, altered states of consciousness, meaningful experiences, subjective experience, neurobiological mechanisms, psychedelic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.